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AbstrAct
Zinc deficiency (ZD) increases the risk of esophageal squamous cell carcinoma 
(ESCC), and marginal ZD is prevalent in humans. In rats, marked-ZD (3 mg Zn/kg diet) 
induces a proliferative esophagus with a 5-microRNA signature (miR-31, -223, -21, 
-146b, -146a) and promotes ESCC. Here we report that moderate and mild-ZD (6 and 
12 mg Zn/kg diet) also induced esophageal hyperplasia, albeit less pronounced than 
induced by marked-ZD, with a 2-microRNA signature (miR-31, -146a). On exposure 
to an environmental carcinogen, ~16% of moderate/mild-ZD rats developed ESCC, 
a cancer incidence significantly greater than for Zn-sufficient rats (0%) (P ≤ 0.05), 
but lower than marked-ZD rats (68%) (P < 0.001). Importantly, the high ESCC, 
marked-ZD esophagus had a 15-microRNA signature, resembling the human ESCC 
miRNAome, with miR-223, miR-21, and miR-31 as the top-up-regulated species. This 
signature discriminated it from the low ESCC, moderate/mild-ZD esophagus, with a 
2-microRNA signature (miR-31, miR-223). Additionally, Fbxw7, Pdcd4, and Stk40 
(tumor-suppressor targets of miR-223, -21, and -31) were downregulated in marked-
ZD cohort. Bioinformatics analysis predicted functional relationships of the 3 tumor-
suppressors with other cancer-related genes. Thus, microRNA dysregulation and ESCC 
progression depend on the extent of dietary Zn deficiency. Our findings suggest that 
even moderate ZD may promote esophageal cancer and dietary Zn has preventive 
properties against ESCC. Additionally, the deficiency-associated miR-223, miR-21, 
and miR-31 may be useful therapeutic targets in ESCC.
INtrODUctION
Esophageal cancer, including esophageal squamous 
cell carcinoma (ESCC) and adenocarcinoma, is the eighth 
most common cancer worldwide and the sixth most 
common cause of death from cancer, with a 5-year survival 
rate of only 10%. In 2012, there were an estimated 456,000 
new cases and 400,000 deaths [1]. Representing 80% 
of cases of esophageal cancer worldwide, ESCC is the 
predominant histological subtype [2]. ESCC is typically 
diagnosed at an advanced stage because early symptoms 
are usually absent. Thus, clarification of pathogenesis 
mechanisms and new methods for prevention, diagnosis, 
and treatment are urgently needed.
Risk factors for ESCC include alcohol and tobacco 
use, nutritional deficiencies, and exposure to environmental 
carcinogens, such as N-nitrosomethylbenzylamine 
(NMBA) [3]. In particular, zinc (Zn) deficiency (ZD) 
(defined as inadequate dietary Zn intake) is implicated in 
the etiology of ESCC in many populations [4-9], including 
people with heavy alcohol consumption [10]. In 2005 
Abnet et al. [11] showed that high esophageal tissue Zn 
concentration was strongly associated with a reduced 
risk of developing ESCC as compared with low tissue Zn 
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concentration; their data provide the strongest evidence in 
humans of an association between dietary ZD and ESCC. 
Previously, we showed that rats on a low Zn diet 
containing 3 mg Zn/kg (hereafter called marked-ZD) 
for 5 weeks develop a hyperplastic esophagus with a 
distinct gene signature that includes upregulation of the 
proinflammation mediators S100a8/a9 [12]. Prolonged 
ZD (23 weeks) leads to an expanded cancer-associated 
inflammatory program that, when combined with non-
carcinogenic low doses of the environmental carcinogen 
NMBA, produced ESCC [13]. In addition, prolonged 
ZD by itself induced an oncogenic microRNA (miRNA) 
signature with miR-31 as the top upregulated species [14], 
a feature of human ESCCs as well [15, 16]. MiRNAs are 
short, non-coding RNAs that regulate gene expression by 
means of translational inhibition and mRNA degradation 
[17]. Each miRNA inhibits multiple target genes or 
entire signaling pathways. Thus, a range of biological 
processes can be affected, including cell proliferation, 
differentiation, and apoptosis. By inhibiting a variety 
of tumor suppressive and oncogenic mRNAs [18, 19], 
miRNAs can act as oncogenes or tumor suppressors 
depending on tissue or cell-type [20]. Alterations in the 
expression of miRNA genes contribute to the pathogenesis 
of most human malignancies [19, 21], including ESCC 
[15, 16, 22-35]. 
Our ZD rat model [12-14, 36-38] recapitulates 
features of human ESCC, including ZD, miRNA 
dysregulation, and inflammation [4, 15, 16, 39]. Thus, 
our model provides an opportunity to better define the 
relationship between dietary Zn intake and miRNA 
dysregulation in ESCC development. This ZD model 
with 3 mg Zn/kg diet is relevant to human health. The 
recommended dietary allowance (RDA) for Zn in males 
is 11 mg (NIH ODS). Assuming an adult male human 
on a 3 mg Zn/kg diet consumes about 1.2 kg (2.64 lb) 
of food/day, his daily Zn intake would be 3.6 mg Zn 
or 33% of RDA for Zn. Thus, this person would be 
considered as markedly-ZD. In rat studies by others [40, 
41], a “severely” ZD diet has less than 1 mg Zn/kg, a 
“marginally” ZD diet has 5 mg Zn/kg, and a “marginally 
“Zn-adequate diet has 10 mg Zn/kg. To extrapolate this to 
human Zn nutrition, a person on a 1, 5, and 10 mg Zn/kg 
experimental diet would have a daily Zn intake of about 
11%, 54%, 108% of human RDA. 
ZD is recognized as a major worldwide public health 
problem [42-46], affecting 31% of the global population 
(4-73%, depending on subregions), with higher rates in 
developing countries [45]. Whereas severe or clinical 
ZD is uncommon, mild-to-moderate ZD is prevalent 
throughout the world [47]. Using a well-characterized ZD 
rat esophageal cancer model [13, 14, 37, 38], the current 
study asks whether moderate-ZD (6 mg Zn/kg diet, 
~66% of human RDA) and mild-ZD (12 mg Zn/kg diet, 
~132% of human RDA) might cause alterations in miRNA 
expression, as does a marked-ZD diet (3 mg Zn/kg, 
~33% of human RDA) that provides a microenvironment 
conducive to ESCC development on exposure to low 
carcinogen doses [14]. For this, we conducted a long-term 
tumor bioassay by low doses of NMBA in rats fed diets 
with different amounts of Zn - 3, 6, 12, or 60 mg Zn/kg 
to represent marked-ZD, moderate-ZD, mild-ZD, and Zn-
sufficiency (ZS), respectively. In parallel, we performed 
miRNA profiling (nanoString platform) in esophageal 
mucosa from NMBA-treated rats at tumor endpoint and 
from NMBA-untreated rats at identical time point in order 
to correlate miRNA expression changes with ZD doses 
and esophageal tumor outcome. 
rEsULts
Dose-response studies with dietary ZD in 
esophageal tumorigenesis
To determine whether moderate-ZD (6 mg Zn/
kg diet) and mild-ZD (12 mg Zn/kg diet) [40, 41] cause 
aberrant miRNA expression and enhance NMBA-induced 
esophageal tumorigenesis, a 22-week tumor study was 
performed. As shown in the study design (Figure 1A), 191 
rats (4-wk-old) were fed diets containing 3, 6, 12, or 60 
mg Zn/kg to form respective ZD3T, ZD6T, ZD12T, and 
ZST (NMBA-treated tumor group, n = 25-27 rats/group), 
and ZD3, ZD6, ZD12, and ZS (diet group without NMBA 
treatment, n = 22 rats/group). Tumor groups received 
four intragastric doses of NMBA (2 mg/kg body weight, 
once/week for four consecutive weeks). At endpoint 
(week 22), miRNA-expression profiling was performed 
on esophageal mucosa-derived RNA from both diet and 
tumor groups. At the same time, esophagi from the tumor 
group were evaluated for tumor incidence. 
First, we determined whether after 5 weeks of 
dietary regimen, moderate and mild-ZD also increased 
esophageal cellular proliferation, as did marked-ZD [38, 
48]. PCNA immunohistochemistry was used to identify 
cells in S-phase [49]. ZD6 and ZD12 esophageal epithelia 
displayed abundant PCNA-positive nuclei in several 
cell layers, including suprabasal layers, although less 
prominent compared to ZD3 esophagus. By contrast, 
PCNA-positive nuclei in ZS esophagus were largely 
restricted to the basal cell layers (Figure 1B, 5-weeks). 
The cell proliferation index (% of intensely stained 
PCNA-positive nuclei) in ZD cohorts, namely, ZD3 
(49±2.9%), ZD6 (39±2.7%), or ZD12 (31±4%) esophagus, 
was significantly greater than ZS esophagus (23±2.9%) 
(P < 0.001) (Figure 1B). Among the ZD cohorts, ZD3 
showed significantly higher PCNA-labeling index than 
ZD6 or ZD12 esophagus (P < 0.001). At the conclusion 
of the study (22-weeks), ZS esophagus remained 
nonproliferative, whereas, ZD6 and ZD12 esophagus 
showed sustained proliferation with PCNA-positive 
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nucleic in focal hyperplastic lesions (FHLs), a result 
consistent with the highly proliferative ZD3 esophagus, 
albeit less pronounced (Figure 1B, 22-weeks). These 
findings demonstrate that moderate/mild-ZD causes 
sustained esophageal cellular proliferation.
At tumor endpoint, serum Zn levels in ZD cohorts 
were significantly lower than in ZS rats (P < 0.001) 
(Figure 1C). Moderate-ZD and ZS rats had comparable 
body weight, because ZS group was paired-fed to 
moderate-ZD rats to match their relative reduced food 
intake (Figure 1C). Moderate/mild-ZD rats also had higher 
body weight than marked-ZD rats, because of reduced 
food consumption in the latter group. 
Regardless of the extent of the deficiency of Zn, 
Figure 1: Dose-response relationship between dietary Zn deficiency and esophageal cancer development. A. Study design 
- 4-week-old rats were fed diets containing 3, 6, 12, or 60 mg Zn/kg, forming marked-ZD (ZD3), moderate-ZD (ZD6), mild-ZD (ZD-12), 
and Zn-sufficient (ZS) groups (n = 47-49/group). After 5 weeks, NMBA-treated tumor (T) groups received 4 intragastric NMBA doses, 
once a week for 4 consecutive weeks (2 mg/kg body weight; n = 26-27 rats/group); control groups were NMBA-untreated (n = 10 rats/
group). The study was concluded 17 weeks after the 1st NMBA dose. B. At 5 weeks after dietary regimen, immunohistochemical analysis 
showing abundant and strong PCNA-positive nuclei (red, 3-amino-9-ethylcarbazole substrate-chromogen) in in multiple cell layers (arrow 
head) in proliferative ZD3, ZD6, and ZD12 esophageal epithelia vs few PCNA-positive nuclei in nonproliferative ZS control (scale bars 
= 100 μm, x100 magnification). Open rectangles are insets illustrated in panels directly below (scale bars = 25 μm, x400 magnification). 
PCNA-LI (labeling index, %) was significantly higher in ZD3 vs ZS, ZD6 vs ZS, ZD12 vs ZS group, and significantly higher in ZD3 
vs ZD6, and ZD3 vs ZD12 group (***P < 0.001, +++P < 0.001, n = 12 rats/group). At 22-weeks, ZD3, ZD6, and ZD12 esophagi showed 
focal hyperplastic lesions (arrow head) with abundant PCNA-positive nuclei vs nonproliferative ZS control (scale bars = 100 μm, x100 
magnification). Open rectangles are insets illustrated in panels directly below (scale bars = 25 μm, x400 magnification). C. Tumor endpoint 
(n = 26-27 rats/group): body weight (g), serum Zn levels (μg/100 ml), esophageal tumor multiplicity (number of tumors/esophagus), tumor 
incidence (%), and esophageal squamous cell carcinoma (ESCC) incidence (%), (ZD tumor group vs ZST control: ***P < 0.001, **P < 0.01, 
*P < 0.05. ZD6T vs ZD3T and ZD12T vs ZD3T: +++P < 0.001, ++P < 0.01, +P < 0.05). Error bars represent standard deviation.
Oncotarget10726www.impactjournals.com/oncotarget
ZD cohorts showed significantly higher tumor incidence 
and multiplicity than ZS rats (Figure 1C; Figure 2A, 
macroscopic view). Moderate and mild-ZD groups 
had similar esophageal tumor incidence (~72%) and 
multiplicity (~4 tumors/esophagus), results that were 
significantly lower than those in marked-ZD (100%, 
14±4.5) but greater than ZS rats (29.6%, 0.92±3.8) (P < 
0.001). Histological examination (H&E-stained sections), 
as well as KRT14 immunostaining (biomarker for ESCC 
[50-52]), showed that 68% (17/25) of ZD3T, 15.4% (4/26) 
of ZD6, and 16% (4/25) of ZD12 rats harbored ESCC. 
Nutritionally complete ZST rats did not develop cancer 
(0/27). All tumors in ZST rats were papillomas [13, 53]. 
The difference in ESCC incidence between ZD12T and 
ZST groups was statistically significant (ZD12T vs ZST, 
P = 0.047) and that between ZD6T vs ZST group was 
close to statistical significance (P = 0.051). These data 
established for the first time that mild and moderate-
ZD enhances esophageal tumorigenesis and promotes 
progression to ESCC. 
Heightened Inflammation accompanies increased 
esophageal tumorigenesis in moderate and mild-
ZD rats
Previously, we reported that marked-ZD (3 mg 
Zn/kg diet) causes upregulation of numerous cancer-
associated inflammation genes that fuel ESCC progression 
[13]. Whether moderate and mild-ZD also causes chronic 
inflammation in the esophagus was evaluated by analyzing 
the expression of six cancer-associated inflammation 
genes (S100a8, S100a9, Cxcl5, Ptgs2, Cxcl2, and Ilb1) 
[13] using quantitative polymerase chain reaction (qPCR). 
Consistent with our previous study [13], the high tumor-
burden, ZD3T esophagus showed upregulation of all six 
inflammation genes compared to its ZST counterpart 
(Figure 2C). Importantly, ZD6T and ZD12T esophagus 
Figure 2: Esophageal tumor development in marked-ZD, moderate-ZD, and mild-ZD rats. A. Macroscopic view of 
representative esophagus from a ZD3T rat showing multiple tumors, ZD6T and ZD12T rats showing sessile tumors, and from a ZST 
showing an occasional papilloma (arrow heads); representative hematoxylin & eosin (H&E)-stained esophageal sections and near serial 
KRT14 (squamous cell tumor marker) immuno-stained sections (brown, 3,3′-diaminobenzidine tetrahydrochloride) showing invasive ESCC 
(arrow head) in ZD3T, ZD6T, and ZD12T esophagi, and a papilloma (arrow) in ZST esophagus. Scale bars = 50 μm, x200 magnification. 
B. Inflammation marker S100A8 and COX-2 showed strong cytoplasmic staining (brown, 3,3′-diaminobenzidine tetrahydrochloride) in 
hyperplastic epithelia and tumor area in ZD3T, ZD6T, and ZD12T esophagus. Scale bars = 50 μm, x200 magnification. C. qPCR analysis 
of mRNA expression of six selected inflammation genes S100a8, S100a9, Cxcl5, Ptgs2, Cxcl2, and Ilb1 (ZD3T vs ZST, ZD6T vs ZST, or 
ZD12T vs ZST group: ***P < 0.001, **P < 0.01, *P < 0.05) (n = 7-10 rats/ group, Oaz1 as normalizer, and error bars represent standard 
deviation). ZD3T, ZD6T, ZD12T, and ZST represent, respectively, marked-ZD, moderate-ZD, mild-ZD, and Zn-sufficient tumor groups.
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Figure 3: Esophageal microRNA expression profiling in Zn modulated rats by nanoString™ nCounter rat miRNA 
expression assay kit. A.-B. Barplots showing fold change of differentially expressed miRNAs in A. NMBA-untreated control esophagi 
at 22-weeks after dietary regimen: ZD3 vs ZS, ZD6 vs ZS, and ZD12 vs ZS group; and B. Tumor bearing esophagi from NMBA-treated 
rats at tumor endpoint: ZD3T vs ZST, ZD6T vs ZST, and ZD12T vs ZST. **Denotes miRNAs that are similarly up- or down-regulated in 
human esophageal squamous cell carcinoma. ZD3 = marked-ZD; ZD6 = moderate-ZD; ZD12 = mild-ZD; ZS = Zn-sufficient. ZD3T, ZD6T, 
ZD12T, and ZST represent the tumor groups (n = 6 rats/group; cut off: P ≤ 0.05, fold-change ≥ 1.3).
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also showed statistically significant upregulation of four 
inflammation genes - S100a8, S100a9, Ptgs2, and Ilb1 
(ZD6T vs ZST, ZD12T vs ZST, P < 0.05 to P < 0.001, 
Figure 2C). Immunohistochemical analyses in ZD6T 
and ZD12T esophagus showed that the upregulation 
observed at the transcript levels for S100a8 and Ptgs2 
was also reflected at the protein level (Figure 2B, S100A8 
and COX-2). These data establish that moderate/mild-
ZD up-regulates key inflammation genes in esophageal 
tumourigenesis [54, 55].
MiRNA expression profiles distinguish the extent 
of ZD in esophagus
To determine the extent of differential miRNA 
expression in esophagus across different doses of dietary 
ZD, we performed miRNA expression profiling in 
ZD3, ZD6, ZD12, and ZS esophageal mucosa using the 
nanoString nCounter rat miRNA expression assay kit (n 
= 6 rats/group) (nanoString Technologies, Seattle, WA). 
This assay detects 423 rat miRNAs. The nanoString 
platform directly measures miRNA expression levels 
without reverse transcription or PCR amplification, 
thereby eliminating enzymatic bias [56, 57]. ZD 
esophageal miRNA profiles, including for ZD3, ZD6, 
and ZD12 cohorts, were different from ZS esophageal 
miRNA profile (Figure 3A). Using a cutoff point of 
P < 0.05 and >1.3-fold difference, we identified 46 
dysregulated miRNAs in ZD3 esophagus (24 up- and 
22 down-regulated), 33 dysregulated miRNAs in ZD6 
(18 up- and 15 down-regulated), and 34 dysregulated 
miRNAs in the ZD12 esophagus (11 up- and 23 down-
regulated) (Figure 3A, Supplementary Table 1). Many 
of the dysregulated miRNAs are similarly dysregulated 
in human ESCC (Figure 3A, marked by asterisks). 
Thus, ZD3 esophagus displayed a 5-miRNA signature 
resembling the miRNAome of human ESCC. The 
signature was defined by five top up-regulated oncogenic 
miRNAs (miR-31, -223, -21, -146b, -146a) [15, 16, 22-
26, 29, 30, 34, 58] that were up 4.9-3.7 fold. This result is 
consistent with our previous study that employed a mouse 
miRNA expression assay kit to profile rat esophagus 
Figure 4: Validation of nanoString miRNA profiling data in Zn-deficient tumor groups by Taqman miRNA assays. 
A. Venn diagram showing miR-223 and miR-31 are common to ZD3T, ZD6T, and ZD12T esophagi (cutoff point of P < 0.05 and fold 
difference >1.3), and scatterplot showing their fold change vs ZST. B. Validation of eight representative miRNAs in ZD3T esophagus; 
and miR-223 and miR-31 in ZD6T and ZD12T esophagi. Quantitative polymerase chain reaction (qPCR) analysis was performed using 
snoRNA and U87 as normalizers (n = 7-10 rats/group). ZD3T, ZD6T, ZD12T, and ZST represent, respectively, marked-ZD, moderate-ZD, 
mild-ZD, and Zn-sufficient tumor groups.
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[14]. Similarly, ZD6 esophagus had a 4-miRNA signature 
(miR-146a, -31, -146b, -27a; up 1.9-1.4 fold) and ZD12 
esophagus a 3-miRNA signature (miR-146a, -31, -223; 
up 1.8-1.4 fold). Notably, miR-31 and miR-146a were 
differentially expressed in ZD6/ZD12 esophagus as they 
were in ZD3 esophagus, albeit at a lower expression level. 
The oncomiR miR-21 that was prominently overexpressed 
(up 4.2 fold) in the highly hyperplastic ZD3 esophagus, 
however, was not differentially expressed in the less 
hyperplastic ZD6 or ZD12 esophagus (Figure 1B: PCNA, 
22 weeks). These findings show that moderate and mild-
ZD induces alterations in miRNA expression, including 
miR-31 and miR-146a. Additionally, miRNA signatures 
distinguish the highly hyperplastic esophageal phenotype 
induced by marked-ZD from the less hyperplastic 
esophageal phenotype induced by moderate and mild-ZD.
MiRNA expression profiles distinguish esophageal 
tumor progression in rats fed different amounts 
of Zn
We next compared the miRNA profiles of tumor-
bearing esophagus across different doses of dietary Zn 
using the nanoString rat miRNA expression assay kit (n 
= 6 rats/group). ZD tumor miRNA profiles (ZD3T, ZD6T, 
and ZD12T) were distinctly different from ZS tumor 
(ZST) profile. Using a cutoff point of P < 0.05 and >1.3-
fold difference, 48 miRNAs were found to be differentially 
expressed in ZD3T esophagus (42 up- and 6 down-
regulated), 23 dysregulated miRNAs in ZD6T esophagus 
(all up-regulated), and 18 in ZD12T esophagus (17 up- and 
1 down-regulated) (Figure 3B, Supplementary Table 2). 
Importantly, the high ESCC-burden, ZD3T esophagus had 
a 15-miRNA signature that resembled the human ESCC 
miRNAome [15, 16, 22, 24-35, 58, 59]. This 15-miRNA 
signature (Figure 3B, marked by asterisks) was defined 
by strong to modest upregulation of oncogenic miR-
223, -21, -31, -146a, -146b, -27a, -221, -27b, -194, -24, 
-203, -183, -130b, -106b, and -22 (up 3.6 to 1.4 fold). By 
contrast, low ESCC-burden, ZD6T and ZD12T esophagus 
displayed, respectively, a 3-miRNA signature (miR-223, 
-31, -27b) and a 2-miRNA signature (miR-223, -31; up 
2.9 and 1.5 fold) with modest upregulation (Figure 3B). 
A Venn diagram (Figure 4A) showed that miR-31, -223, 
-7i, -543 were the four common miRNAs shared among 
ZD3T, ZD6T and ZD12T esophagus. Among which, miR-
31 [15, 16, 30, 60] and miR-223 [25, 26, 34] are oncomiRs 
for human ESCC. Thus, moderate and mild-ZD induces 
alterations in miRNA expression, including miR-31 
and miR-223. In addition, our data show that miRNA-
signatures can distinguish the divergent ESCC progression 
in marked-ZD vs moderate/mild-ZD rat cohorts.
Validation of nanoString miRNA expression 
profiling data
To validate the nanoString miRNA results, we 
performed Taqman miRNA expression assays using qPCR 
and two normalizers - snoRNA and U87 (n = 7-10 rats/
group). We selected 8 miRNAs in ZD3T esophageal tissue 
Figure 5: Localization of miR-223, miR-31, and miR-21 in human esophageal squamous cell carcinoma (ESCC) tissue 
by in situ hybridization (ISH). Representative hematoxylin and eosin [H&E]-stained sections of ESCC tissues (2 cases) are shown. 
miR-223, -31, and -21 ISH signal (blue, 4-nitro-blue tetrazolium and 5-brom-4-chloro-3′-indolylphosphate; counterstain, nuclear fast red) 
was moderate to intense and abundant in near serial formalin-fixed, paraffin-embedded sections of ESCC tumor tissue. Scale bars = 50 μm, 
x200 magnification.
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(miR-223, -21, -31, -146a, -146b, -221, -194, and -106b) 
and two miRNAs (miR-31, -223) in ZD6T and ZD12T 
esophageal tissues, Figure 4B shows that the Taqman 
data confirmed the upregulation of all 8 selected miRNAs 
in ZD3T vs ZST samples, and the upregulation of miR-
223 and miR-31 in ZD6T and ZD12T samples. The same 
fold changes response to dietary ZD was observed using 
Taqman as with the nanoString platform. 
Cellular localization of miR-223, miR-31 and 
miR-21 expression in human ESCC tissue
The cellular origins of miRNAs are of importance to 
their mechanistic roles in cancer development. Previously, 
we demonstrated an abundant miR-31 ISH signal in 
human ESCC tissue [60]. Whether miR-223 and miR-
21 co-localize in the same ESCC tissue is not known. 
Thus, we evaluated the cellular localization of all three 
miRNAs in archived FFPE human ESCC tissues using 
in situ hybridization (ISH) (n = 12 cases). All 12 cases 
showed intense to moderate miR-31, miR-223, and miR-
21 ISH signal in near serial sections of moderately to 
poorly differentiated ESCC tumor samples (Figure 5). By 
contrast, the normal mucosa adjacent to the tumor cells 
had very weak staining (data not shown). These results 
represent the first simultaneous in situ detection of miR-
223, -21, and -31 in human ESCC. 
miR-223, -31, -21 upregulation correlates with 
down-regulation of their tumor-suppressor targets
We then determined whether upregulation of 
oncogenic miR-223, -31, and -21 in ZD3T, ZD6T, and 
ZD12T esophagus is accompanied by down-regulation of 
their respective tumor suppressor targets, FXBW7 [25, 61], 
STK40 [60, 62, 63], and PDCD4 [64], by using qPCR (n 
= 7-10 rats/group). The mRNA levels of Fbxw7 and Stk40 
in all 3 ZD tumor groups were statistically significantly 
reduced as compared to ZST esophagus (**P < 0.01, 
***P < 0.001). Pdcd4 was significantly reduced only in 
ZD3T and ZD6T esophagus vs its ZST counterpart (*P < 
0.05, ***P < 0.001) (Figure 6A). Immunohistochemical 
analysis showed that FBXW7, STK40, and PDCD4 
protein was moderately/strongly expressed in the basal/
suprabasal cells of ZST esophagus, but reduced or absent 
in hyperplastic/tumor-bearing ZD3T, ZD6T, and ZD12T 
esophagus (Figure 6B). Thus, upregulation of oncogenic 
miR-223, -31, and -21 is accompanied by down-regulation 
Figure 6: Analysis of esophageal expression of Fbxw7, Stk40, and Pdcd4 (respective tumor suppressor targets of miR-
223, miR-31, and -21) in Zn-modulated rats at tumor endpoint. A. Quantitative polymerase chain reaction (qPCR) analysis 
of esophageal Fbxw7, Stk40, and Pdcd4 expression in three ZD tumor groups (n = 7-10 rats/group; Oaz1 as normalizer). Fbxw7 and 
Stk40 expression was significantly downregulated in ZD3T, ZD6T, and ZD12T group vs ZST group. Pdcd4 expression was significantly 
downregulated in ZD3T and ZD6T group vs ZST group. ***P < 0.001, **P < 0.01, *P < 0.05. Error bars represent standard deviation. 
B. Immunohistochemical (IHC) analysis of FBXW7, STK40, and PDCD4 protein expression. IHC showing reduction of FBXW7 
and STK40 protein expression (nuclear, cytoplasmic) in ZD3T, ZD6T, and ZD12T esophagus, compared to ZST esophagus (brown, 
3,3′-diaminobenzidine tetrahydrochloride). Nuclear PDCD4 protein expression was largely absent in ZD3T esophagus and greatly reduced 
in ZD6T and ZD12T compared to ZST (red, 3-amino-9-ethylcarbazole substrate-chromogen). ZD3T, ZD6T, ZD12T, and ZST represent, 
respectively, marked-ZD, moderate-ZD, mild-ZD, and Zn-sufficient tumor groups. Scale bars = 25 μm, x400 magnification.
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of their respective tumor suppressor target Fbxw7, Stk40 
and Pdcd4.
Esophagus-specific functional relationship 
prediction among tumor-suppressor targets
Functional Networks of Tissues in Mouse (FMTN) 
[65, 66] is a prediction tool for tissue-specific protein 
interactions for the mouse that is based on the integration 
of a variety of genomic data and prior knowledge of gene 
function. To explore the esophagus-specific functional 
relationships for Fbxw7, Stk40, and Pdcd4 (tumor-
suppressor targets of miR-223, -31, -21), we employed 
FNTM for the rat. The percentage of orthologous genes 
shared by mouse and rat is very high, and a similar tool is 
not available for the rat. We obtained a nine-gene network 
of functional relationship predictions in the esophagus 
(Figure 7A) showing that Fbxw7, Stk40, and Pdcd4 were 
functionally related to several cancer-related genes, such as 
Pten, tumor suppressor of miR-21 [67, 68], oncogene Bcl2 
[69], a Wnt signaling pathway transcription factor Tcf4 
[70], the dead box protein family of RNA helicases Ddx6 
[71, 72], fibroblast growth factor receptor 1 Fgfr1 [73-75], 
and Ppp3ca, a component of calcium/calcineurin signaling 
that includes apoptosis [76]. Enrichment Gene Ontology 
analysis showed that Pten, Bcl2, Ppp3Ca, and Fgfr1 were 
the genes most functionally related to Fbxw7, Stk40, and 
Pdcd4 and were statistically significantly enriched in 
Figure 7: Esophagus-specific functional relationship network among Fbxw7, Stk40, and Pdcd4 using the Functional 
Networks of Tissues in Mouse (FNTM) prediction tool. A. The displayed esophagus-specific nine-gene network shows predicted 
functional relationships among the genes that are most functionally related to Stk40, Pdcd4 and Fbxw7 (tumor-suppressor targets of 
miR-31, mir-21 and miR-223, respectively). The edges between genes are colored by the confidence of the predicted relationship. B. 
Enrichment Gene Ontology analysis for the nine genes retrieved from FNTM analysis. Terms exceeding an FDR-corrected P-value of 
0.01 are excluded. C. Quantitative polymerase chain reaction (qPCR) analysis of esophageal Pten expression in ZD3T and ZST esophagus 
(n = 6 rats/group; Oaz1 as normalizer, *P = 0.02). Error bars represent standard deviation. D. Immunohistochemical analysis of PTEN 
protein expression in ZD3T and ZST esophagus showing cytoplasmic PTEN expression in ZST esophageal epithelial cells (black arrow 
head, brown, 3,3′-diaminobenzidine tetrahydrochloride) and lack of PTEN expression in ZS3T esophageal ESCC tumor cells Stromal cells 
and blood vessels showed intensely positive expression for PTEN (red arrow head, served as integral internal positive). ZD3T and ZST = 
marked-ZD and Zn-sufficient tumor groups. Scale bars = 25 μm, x400 magnification.
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biological processes related to cell cycle, growth, response 
to stress, and apoptosis regulation (Figure 7B). We then 
showed that the expression of the most functionally related 
gene, Pten, was also down-regulated in the ESCC-bearing 
ZD3T esophagus that overexpressed miR-21 at the mRNA 
level by qPCR (P = 0.02, n = 6 rats/group) and at the 
protein level by immunohistochemistry compared to ZS 
counterpart (Figure 7C). That the three tumor suppressor 
targets are predicted to interact to alter network of cancer-
related proteins [65, 66, 77] provide support that miR-223, 
miR-21, and miR-31 have an important role in ESCC and 
may be useful therapeutic targets in ESCC. 
DIscUssION
In humans, low dietary Zn intake is associated with 
an increased risk of ESCC [7, 9]. Although marginal ZD 
is prevalent in humans [47], the effect of moderate ZD 
on the etiology of ESCC has not been studied. Using a 
well-characterized ZD rat esophageal cancer model [13, 
14, 37, 38], the current study demonstrates for the first 
time that ESCC initiation and progression, as well as 
miRNA dysregulation, depend on the extent of deficiency 
of dietary Zn. 
Sustained increased cellular proliferation is a 
hallmark of cancer [78]. Previously, we reported that 
marked-ZD (3 mg Zn/kg) induces prominent esophageal 
cellular proliferation, predisposing to tumor development 
[13, 79]. We now show that a moderately-ZD (6 mg Zn/
kg) and a mildly-ZD (12 mg Zn/kg) diet also induced 
a sustained but less-pronounced, esophageal cellular 
proliferation. Importantly, in the presence of moderate 
or mild-ZD, low NMBA doses elicited statistically 
significantly higher tumor incidence/multiplicity, as well 
as ESCC progression than with Zn sufficiency (Figure 
1C). Although marked-ZD led to significantly higher 
tumor/ESCC incidence than moderate or mild-ZD, no 
statistically significant difference was obtained in tumor 
or ESCC outcome between moderate-ZD and mild-ZD, 
despite a two-fold difference in Zn content. These data 
show a dose-response relationship between the extent of 
ZD and ESCC development. Additionally, they provide 
the first evidence that moderate to mild-ZD, combined 
with low doses of the environmental carcinogen NMBA, 
produces ESCC. 
MiRNA-expression profiling of human tumors has 
identified signatures associated with staging, progression, 
prognosis, and response to treatment [21]. Also, miRNA 
expression patterns have been shown to be potential 
classifiers for ESCC [29]. Using the nanoString platform, 
miRNA expression profiles distinguished the highly 
preneoplastic/proliferative marked-ZD esophageal 
phenotype with a 5-miRNA signature (miR-31, -223, 
-21, -146b, -146a), from the less proliferative, mild-ZD 
phenotype with a 3-miRNA signature (miR-146a, -31, 
-223). Importantly, the high ESCC-burden, marked-ZD 
esophagus showed a 15-miRNA signature (with miR-
223, -21, and -31 as the top-up-regulated species), thus 
differentiating it from the low ESCC-burden, mild-ZD 
esophagus with a 2-miRNA signature (miR-223, -31). In 
addition, our data show that these miRNA signatures not 
only differentiate esophageal preneoplasia from normal 
esophagus and stages of ESCC progression, but also 
highlight the molecular impact of dietary ZD on miRNA 
dysregulation in the pathogenesis of ESCC. 
miR-223, miR-21, and miR-31 are the top-
upregulated species in the high ESCC-burden, marked-
ZD esophagus. In addition, miR-223 and miR-31 
dysregulation is common to marked-ZD and moderate/
mild-ZD tumor groups (Figure 4A). Recently, we 
demonstrated by ChIP-seq analysis that in ZD esophagus, 
the miR-31 promoter region and NF-κΒ binding site 
were activated, unleashing miR-31-associated STK40-
NF-κΒ controlled inflammatory signaling to produce a 
preneoplastic phenotype; Zn-replenishment restores the 
normal regulation of this genomic region and a normal 
esophageal phenotype [60]. The mechanism(s) by which 
miR-223 and miR-21 are upregulated by ZD remains to 
be elucidated. 
miR-223, miR-21, and miR-31 can target many 
important tumor suppressor genes, including FXBW7 
[25, 61], STK40 [60, 62, 63], and PDCD4 [64]. miR-223 
acts as an oncomiR in several solid tumors, including 
ESCC, gastric, ovarian, and bladder cancers [25, 80-82]. 
In ESCC, patients with high miR-223 expression have 
a significantly poorer prognosis, presumably because 
of repression of the function of its tumor suppressor 
target FBXW7 [25]. FBXW7 is a cell cycle protein that 
regulates the stability of several oncoproteins, including 
cyclin E, c-Myc, and c-Jun [83]. miR-21 is one of the most 
consistently overexpressed oncomiRs in solid cancers [84], 
including ESCC [22-24, 29]. A genuine oncogene, mice 
conditionally overexpressing miR-21 develop lymphoma 
[85]. Oncogenic miR-21 exerts its anti-apoptotic effects 
by targeting the tumor suppressors PDCD4 and PTEN 
[64, 67]. PDCD4 is one of the most frequently down-
regulated proteins in esophageal cancer [86]. miR-31 
acts as an oncomiR in squamous cell carcinomas (SCCs), 
including ESCC [15, 16], tongue SCC [87], head and neck 
SCC [88], and skin SCC [89]. STK40 is a known negative 
regulator of NF-κΒ mediated transcription [90] and a miR-
31 direct target [60, 62, 63]. That the tumor suppressor 
genes Fxbw7, Pdcd4, and Stk40 were downregulated at 
the mRNA and protein level in marked-ZD tumor group 
(Figure 6) and that they were predicted to interact to 
alter network of target proteins [65, 66, 77] (Figure 7) 
provide support that miR-223, miR-21, and miR-31 have 
an important role in ESCC and may be useful prognostic 
biomarkers and therapeutic targets for ESCC. 
A limitation of this study is the fact that the 
underlying biological mechanisms of the key dysregulated 
miRNAs in ESCC development, namely, miR-223, miR-
Oncotarget10733www.impactjournals.com/oncotarget
21, and miR-31, were not investigated. Studies are in 
progress to specifically address this issue.
In summary, this dose-response study demonstrates 
that ESCC development and the underlying miRNA 
dysregulation are dependent on the extent of deficiency 
of the nutrient Zn. Although it remains to be determined 
if the results in this ZD dose-response study in the rat 
will translate to human ESCC, our findings suggest that 
dietary Zn may have preventive properties against ESCC 
and provide a mechanistic rationale for exploring the 
therapeutic use of Zn against ESCC. In addition, our study 
has identified Zn deficiency-associated miRNA signatures 
that may underlie the molecular pathogenesis of ESCC in 
Zn-deficient populations. Our study suggests that miR-
223, miR-31 and miR-21 alone or in combination could 
be used as therapeutic targets for treatment of ESCC. 
MAtErIALs AND MEtHODs
Animals, Zn-adjusted diets, and carcinogen
Male weanling Sprague-Dawley rats (50 ± 5 g) were 
obtained from Taconic Laboratory (Germantown, NY). 
Four egg white-based, Zn-adjusted diets, hereafter called 
ZD3, ZD6, ZD12, and ZS, containing 3, 6, 12, and 60. 
respectively, (mg Zn/kg diet), were from Harlan Teklad 
(Madison, WI). The diets were shape and color-coded to 
ensure the animals were fed the assigned food. NMBA 
was from Midwest Research Institute (Kansas City, MO).
Experimental design
Animal protocols were approved by the Thomas 
Jefferson University Institutional Animal Care and Use 
Committee. Weanling male rats were randomly divided 
into 4 dietary groups (ZD3, ZD6, ZD12, and ZS, n = 47-
49 rats/group) and were tail-tattooed for identification. 
ZD rats were fed ad libitum and ZS rats were pair-fed to 
ZD6 animals to match the decreased food consumption 
of ZD6 rats [38]. After 5 weeks, 12 rats per group were 
killed for evaluation of esophageal cell proliferation 
[38]. The remaining animals were divided into NMBA-
treated groups (n = 25-27 rats/dietary group) and NMBA-
untreated groups (10 rats/group). Carcinogen-treated rats 
were administered intragastrically 4 NMBA doses (2 mg/
kg body weight), once a week for 4 consecutive weeks. 
NMBA-untreated groups received saline. The animals 
were weighed weekly and monitored daily. The study 
was concluded at 17 weeks after the 1st NMBA dose (22 
weeks of ZD). At sacrifice, the animals were anesthetized 
by delivering isoflurane (GE Healthcare) to the respiratory 
tract of the rat using a vaporizer at 3% concentration. 
Blood was obtained from the retro-orbital venous plexus 
for serum preparation and subsequent Zn analysis. Whole 
esophagus was excised and longitudinally slit open. 
Tumors greater than 0.5 mm in diameter were mapped.
Esophageal epithelia preparation
Esophagi were isolated and cut into two equal 
portions. Esophageal epithelium was prepared from a 
portion by using a blade to remove the submucosal and 
muscularis layers, snap-frozen in liquid nitrogen and 
stored at -80°C [13]. The remaining portion was fixed in 
10% buffered formalin and paraffin embedded.
rNA isolation
Esophageal epithelial samples frozen in liquid 
nitrogen were pulverized to a fine powder using a chilled 
hammer. Total RNA was extracted from the pulverized 
samples using an animal tissue RNA extraction Kit 
(#25700, Norgen Biotek, Ontario, Canada). RNA 
concentration of each sample was determined using a 
NanoDrop 1000 (Thermo Scientific). All RNA samples 
displayed a 260:280 ratio >1.8, and a 260:230 ratio > 1.8.
nanoString rat miRNA expression assay
The nanoString rat miRNA expression assay kit that 
profiles 423 rat miRNAs was employed (n = 6 rats/group). 
This assay was performed at the Ohio State University 
Comprehensive Cancer Center Genomics Shared Resource 
according to manufacturer’s instruction. Briefly, 100 ng 
of total RNA was used as input material. Small RNA 
samples were prepared by ligating a specific DNA tag onto 
the 3’ end of each mature miRNA. These tags normalized 
the melting temperatures (Tms) of the miRNAs and 
provided identification for each miRNA species in the 
sample. Excess tags were then removed, and the resulting 
material was hybridized with a panel of miRNA:tag-
specific nCounter capture and barcoded reporter probes. 
Hybridization reactions were incubated at 640C for 18 
h. Hybridized probes were purified and immobilized on 
a streptavidin-coated cartridge using the nCounter Prep 
Station. nCounter Digital Analyzer was used to count 
individual fluorescent barcodes and quantify target RNA 
molecules present in each sample. For each assay, a high-
density scan (600 fields of view) was performed.
nanostring data analysis
Abundances of miRNAs were quantified using the 
nanoString nCounter gene expression system [56]. Each 
sample was normalized using the global sum method that 
uses the entire miRNA content. The nanoString nSolver 
software tool was used to facilitate normalization. 
Student’s t-test was used to calculate statistical 
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significances of pair-wise comparisons. Calculations were 
performed using the R statistical computing environment 
(http://www.r-project.org/).
TaqMan miRNA assay
Reverse transcription of miRNAs was performed 
according to the manufacturer’s instructions (Applied 
Biosystems, Foster City, CA) with a reaction volume of 
15 μl containing 350 ng of total RNA. The real-time PCR 
was performed using the 7300 Real-Time PCR Systems 
(Applied Biosystems). Each miRNA and endogenous 
control (snoRNA and U87) was measured in triplicates. 
As an overall quality control, CT values above 35 were 
excluded from analysis.
In situ hybridization
miRCURY locked nucleic acid (LNA)™ 
microRNA detection probes, namely, rno-miR-21, 
rno-miR-31, rno-miR-223, hsa-miR-31, hsa-miR-223, 
negative controls (rno-miR-31) with mismatches at 
two position, were purchased from Exiqon (Vedbaek, 
Denmark). The oligonucleotides are double DIG-labeled 
at the 5’- and 3’-ends. ISH was performed on 6 µm FFPE 
sections as described by Nielsen et al. [91]. Following 
deparaffinization, rehydration in graded alcohol and 
proteinase K treatment, tissue sections were hybridized 
with miR-31 probe (20 nM), miR-223 or miR-21 probe 
(50 nM) in hybridization buffer (Exiqon) at 50 oC - 57oC 
for 14 h in a hybridizer (Dako, Glostrup, Denmark). 
Following stringent washes in SSC buffers, the sections 
were blocked against unspecific binding of the detecting 
antibody, using DIG wash and blocking reagent. miRNA 
was localized by incubation with 4-nitro-blue tetrazolium 
(NBT) and 5-brom-4-chloro-3′-indolylphosphate (BCIP) 
(Roche, Mannheim, Germany). Nuclear fast red (Vector 
Lab., Burlingname, CA) was used as a counterstain. 
Quantitative real time PCR
cDNA was reverse transcribed using the High-
Capacity cDNA Archive Kit (Applied Biosystems, 
Foster City, CA) using reverse transcription reaction 
volumes of 20 μl containing 1 μg of total RNA for each 
sample according to the manufacturer’s protocol. qPCR 
was performed using pre-designed probes (Applied 
Biosystems), Psmb6 and Oaz1 as the normalizers, and the 
comparative Ct method .
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded (FFPE) tissues 
were deparaffinized, and rehydrated in graded alcohols. 
IHC was carried out as previously described [37, 38, 
60] using primary antibodies for PCNA (clone PC-10, 
Ab-1, Thermo Scientific, Waltham, MA, USA), KRT14 
(NCL-LL002, Novocastra, Buffalo Grove, IL, USA), 
COX-2 (#12282, Cell Signaling, Danvers, MA, USA), 
S100A8 (T-1032, BMA, Augst, Switzerland), PDCD4 
(LS-B1388, Lifespan Biosciences, Seattle, WA), STK40 
(orb101780, Biorbyt, Cambridge, United Kingdom), 
FBXW7 (ab109617, Abcam, Cambridge, MA, USA), 
and PTEN (#9188, Cell Signaling) after citrate-based 
antigen retrieval. Protein was localized by incubation 
with 3-amino-9-ethylcarbazole substrate-chromogen 
(Dako, Carpinteria, CA, USA) or 3,3’-diaminobenzidine 
tetrahydrochloride (Sigma-Aldrich, St Louis, MO, USA).
Microscopy
IHC and ISH analyses were performed by light 
microscopy using an Olympus BX51 microscope and 
photographs taken with a Spot RT3 camera and Spot 
software v. 4.6.
Zn measurement
Serum Zn content was determined using Atomic 
Absorption Spectrometer Analyst 400 (PerkinElmer, 
Waltham, MA). 
Statistical analysis
Dietary Zn effects on continuous data (tumor 
multiplicity, serum Zn, weight) were analyzed by 
analysis of variance (ANOVA). Differences among the 
groups were assessed using the Tukey-HSD multiple 
comparisons post hoc t-tests. When the data exhibited 
heteroscedasticity (tested by Levene’s homogeneity of 
variance test), the Welch ANOVA test was used to detect 
an overall difference in the dietary groups and the Games-
Howell pairwise comparison test was used for detecting 
differences among the groups. For data where only 2 
groups were analyzed or for the inflammation genes where 
we were only interested in detecting differences between 
the zinc sufficient group and each zinc deficient group, the 
students t-test was used to compare the groups. Dietary 
group effects in tumor/ESCC incidence were assessed by 
an overall chi-square test. Pairwise Fisher’s exact test was 
used to compare the individual dietary groups. Statistical 
tests were 2-sided and were considered significant at P < 
0.05. Statistical analysis was performed using R (http://
www.R-project.org).
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